Professional Supplements for Wise Athletes (click to see the huge "always on" discount)

• Board certified in internal medicine and obesity medicine, with a long focus on immunometabolism.
• Her book, The Architecture of Enough: Hunger, GLP-1, and the Immune Metabolic System, is available on Amazon (paperback: https://www.amazon.com/Architecture-Enough-Hunger-Immune-Metabolic/dp/B0H2R8HKS4 — and Kindle) and Barnes & Noble.
• She also publishes an in-depth health e-zine at wellth-e.com (WELLTH-E — "wealth" as in money plus wellness); she points listeners to issue #3

Bottom line: For an otherwise healthy, fit person chasing a modest amount of weight, Dr. Loh's take is stay away if you can — the muscle and immune-metabolic costs outweigh the benefit, and these drugs are best reserved for clear medical need, used with a real clinician and a defined exit strategy.

*Note: Educational, not medical advice. Dr. Loh stresses these decisions should be made with a clinician genuinely involved in your care.*

1. Ask "where's the receptor?" to tell a direct drug effect from a general weight-loss effect.
2. Metabolism and immunity are inseparable — every metabolic change is an immune change.
3. Insulin resistance is an adaptive response; acute is healthy, chronic is the problem.
4. The drug delivers GLP-1 alone and supraphysiologically — missing the natural hormone "family" and overriding your own system.
5. GLP-1 curbs appetite partly by inducing a low-grade "sickness" state via IL-6.
6. IL-6 isn't just "bad"; suppressing it long-term may drive muscle loss and impair repair.
7. Biggest risk for fit people: trading fat for lost muscle (obesity+diabetes → sarcopenia+diabetes).
8. ~75% regain most weight within a year of stopping, even while keeping good diet habits.
9. Beware catabolic states — surgery, illness, immobility — while on these drugs.
10. Skip no-follow-up, online platforms; pair any GLP-1 use with real lifestyle structure (meals, protein, hydration, sleep, lifting).

• Two years after her last appearance, Dr. Vyvyane Loh returns to tackle the drugs everyone's asking about — the GLP-1s (Ozempic, Wegovy, semaglutide). Joe comes in tempted, like a lot of listeners: not a hundred pounds to lose, just a stubborn ten and the promise that these drugs are also good for your heart, kidneys, liver, and longevity. Dr. Loh's job in this episode is to separate what's real from what's hype — and to explain what these drugs may be costing that the marketing never mentions.
• Her first tool for cutting through the noise is a simple question: "where is the GLP-1 receptor?" If a supposed benefit is happening in a tissue that has no GLP-1 receptor, it's probably just a general effect of losing weight (better sleep apnea, less inflammation) — not a direct, magical property of the drug. Much of the "good for everything" story, she argues, is really just "weight loss is good for people who were carrying excess fat."
• The conceptual heart of the episode is her core thesis: metabolism and the immune system are the same conversation. Any metabolic intervention is also an immune intervention, and vice versa. She reframes insulin resistance not as a villain but as a natural, adaptive response — during infection, inflammation, or pregnancy, the b...

Professional Supplements for Wise Athletes (click to see the huge "always on" discount)

Guido Claessen is a Belgian sports cardiologist, physician-scientist (MD, PhD), and academic specializing in sports cardiology, exercise physiology, and advanced cardiovascular imaging. His research focuses on how intensive exercise affects the heart, distinguishing normal athletic adaptations from heart disease, and improving the diagnosis and treatment of cardiovascular conditions.

Summary

Sports cardiologist Guido Claessen — principal investigator on the Pro@Heart and Master@Heart studies out of KU Leuven and University of Hasselt — joins Joe to untangle one of the most uncomfortable questions in masters endurance sport: can you exercise too much for your heart? His answer is nuanced. The benefits of exercise are enormous and not in dispute: athletes live at least as long as the general population, probably longer, with far better quality of life. The benefit curve is steep early — the biggest gains come from going from sedentary to even an hour a week — and continues deepening to roughly three to six hours weekly before it plateaus. Past that point, Claessen argues, you're training for love of the sport, not for extra protection on the heart.

The harder material is what his own coronary-CT data revealed. Lifelong athletes in Master@Heart carried more coronary plaque than even very healthy active controls — the opposite of what his team expected. But the story doesn't end there: compared with a typical sedentary population, athletes' plaque skews toward the calcified, stable, rupture-resistant kind, which may be relatively protective. And the single most important caveat threaded through the whole conversation is that nobody yet knows whether that extra plaque actually translates into more heart attacks — the outcome data isn't in. Claessen closes with the practical throughline for older athletes: fitness is not a free pass. Screen the hidden risk factors — Lp(a), ApoB, home blood pressure — treat what needs treating, and don't fear the statin conversation, because the alternatives are now excellent. The takeaway isn't do less; it's do it with your eyes open.

Key learnings

• Don't fear exercise — the longevity case is settled. Even very high training loads are associated with living at least as long as the general population, with major quality-of-life gains on top. There is no signal pointing toward becoming sedentary.
• "Risk" is not one thing. Atrial fibrillation is more common in endurance athletes but it's a manageable nuisance, not sudden cardiac death. Disaggregating AFib from coronary disease from sudden death dissolves a lot of needless fear.
• The benefit curve plateaus around 3–6 hours/week. The steepest gains come early; beyond the plateau, extra volume is a hobby choice, not added heart protection.
• The athlete's heart is built by duration, not intensity. Counterintuitively, cumulative training volume — not how hard you go — drives cardiac enlargement. Tour-level pros trained less intensively than masters athletes yet had larger hearts.
• Lifelong athletes carry more coronary plaque — but more of the stable kind. More plaque than healthy controls (a surprise), yet compared with sedentary people it's more calcified and rupture-resistant.
• The crucial unknown: more plaque ≠ proven more events. Whether higher plaque burden in high-volume athletes leads to more heart attacks is genuinely undetermined; longitudinal follow-up is ongoing. This is the load-bearin...

Professional Supplements for Wise Athletes (click to see the huge "always on" discount)

Affordable (best pricing by far) Blood Testing at GoodLabs (use code WISE for 20% discount)

• Dr. Mike blends deep academic knowledge with practical, field-tested insights to burn fat, build strength, and recover more effectively.PhD in Exercise Physiology from University of Minnesota
• BA in Natural Science from St. Scholastica
• MS in Biomechanics from Michigan Technological University
• Adjunct Professor in Human Performance for Carrick Institute for Functional Neurology

• Mike T Nelson website
• Dr Mike's Newsletter signup link

There's a fight on the internet about VO₂max. One camp treats it as the single number that rules your healthspan — get it as high as humanly possible, no matter the cost. Another camp says it's overhyped, mismeasured, and not worth your attention at all. As usual, the loudest voices are the least useful.

So I brought the question to someone I actually trust: Dr. Mike T. Nelson, back on the show for his fourth conversation with me. Mike is the rare internet fitness voice with both the science and the scruples, and he's written about this exact controversy. My question for him was simple and a little selfish: I'm 64, I don't have unlimited time or unlimited recovery. How much should someone like me actually be chasing VO₂max — and once I've got "enough," where should my effort go instead?

His answer is what this episode is about, and it comes down to a sweet spot. Yes, VO₂max is one of the most powerful longevity predictors we've ever measured — climbing out of the bottom of the pack buys you more protection than almost anything else you can do. But the benefit curve flattens. There's a point where squeezing out another few percent costs enormous effort for very little return — effort that would do far more good aimed at whatever your real weak link is.

Along the way Mike takes apart some sacred cows. Why zone 2, for most of us, is not the magic everyone says it is. How to actually program intervals so you're building speed instead of just collecting misery. Why your fading max heart rate might be partly a use-it-or-lose-it problem. And how something as quiet as your breathing rate while you sleep can tell you whether you're sabotaging your own oxygen delivery.

If you've ever stared at the VO₂max number on your watch and wondered whether to celebrate it, panic about it, or ignore it — this one's for you.

1. VO2max predicts longevity — strongly, but with a caveat. The mortality benefit of moving from very unfit to fit appears larger than almost any other measured intervention, exceeding smoking cessation. But most of that effect comes from rescuing the bottom of the range, not pushing an already-good number higher. (Human observational data; reverse causality is a standing confounder.
2. The "VO2max is overblown" controversy is mostly noise. The complaint that studies use METs and submax estimates rather than gold-standard lab tests is technically correct — but the surrogates and the lab measures largely agree, so the distinction doesn't change the practical conclusion.
3. VO2max is limited by your weakest link — either oxygen delivery (heart, blood flow) or oxygen utilization(muscle, mitochondria). T...